Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 8/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179214 | 0.87 | ALDH1A1 (0.46) | NAMPTGRM5LNPEPBTK | |
| SCHEMBL31510790 | 0.86 | NAMPT (0.52) | NAMPTGRM5GRM1GPR119LNPEP | |
| SCHEMBL1698738 | 0.84 | GPR119 (0.55) | NAMPTGRM5GRM1GPR119PDK4 | |
| SCHEMBL30736635 | 0.84 | GPR119 (0.55) | NAMPTGRM5GRM1GPR119PDK4 | |
| SCHEMBL31612894 | 0.84 | NAMPT (0.53) | NAMPTGRM5GRM1GPR119PDK4 | |
| SCHEMBL1698955 | 0.84 | NAMPT (0.53) | NAMPTGRM5GRM1GPR119PDK4 | |
| SCHEMBL31612893 | 0.84 | NAMPT (0.53) | NAMPTGRM5GRM1GPR119PDK4 | |
| SCHEMBL8195218 | 0.82 | NAMPT (0.57) | NAMPTGRM5GRM1GPR119PDK4 | |
| SCHEMBL6042528 | 0.82 | NAMPT (0.49) | NAMPTGRM5GRM1GPR119LNPEP | |
| SCHEMBL25201639 | 0.81 | NAMPT (0.50) | NAMPTGRM5GRM1GPR119LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | NAMPT 4668/4885GRM5 457/4885GRM1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.